gefitinib has been researched along with Melanoma in 17 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (23.53) | 29.6817 |
2010's | 10 (58.82) | 24.3611 |
2020's | 3 (17.65) | 2.80 |
Authors | Studies |
---|---|
Chang, Y; Cheng, H; Ding, K; Lu, J; Lu, X; Luo, J; Ren, X; Tu, Z; Zhang, L; Zhang, Q | 1 |
Beloueche-Babari, M; Delgado-Goñi, T; Galobart, TC; Leach, MO; Normantaite, D; Wantuch, S; Whittaker, SR | 1 |
Flaherty, K; Guhan, S; Ji, Z; Kumar, R; Njauw, CN; Rajadurai, A; Reddy, B; Tsao, H | 1 |
Andreucci, E; Biagioni, A; Bianchini, F; Calorini, L; Chillà, A; Del Rosso, M; Fibbi, G; Guasti, D; Laurenzana, A; Margheri, F; Menicacci, B; Mocali, A; Paoli, P; Peppicelli, S; Serratì, S | 1 |
Chen, CM; Cheng, CY; Lin, KY; Lu, CY; Wu, YH | 1 |
Hou, W; Wan, X; Zhang, L; Zhu, Y | 1 |
Boespflug, A; Kaya, A; Kaya, G; Saurat, JH; Saxer-Sekulic, N; Sorg, O; Thomas, L | 1 |
Amaro, A; Angelini, G; Esposito, AI; Lanza, F; Mirisola, V; Mosci, C; Musso, A; Nasciuti, F; Perri, P; Pfeffer, U; Poggi, A; Puzone, R; Salvi, S; Tosetti, F; Truini, M | 1 |
Uhara, H | 1 |
Abdiu, A; Djerf, EA; Hallbeck, AL; Thunell, LK; Trinks, C; Walz, TM | 1 |
Elenius, K; Grenman, R; Iivanainen, E; Kulmala, J; Lauttia, S; Salven, P; Tvorogov, D; Zhang, N | 1 |
Katsifis, A; Lin, HQ; Meriaty, H | 2 |
Bar-Eli, M; Bassett, RL; Bedikian, AY; Bronstein, Y; Dobroff, A; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Prieto, VG; Vardeleon, AG; Zigler, M | 1 |
Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO | 1 |
1 review(s) available for gefitinib and Melanoma
Article | Year |
---|---|
[Molecular target therapies for skin cancers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; CTLA-4 Antigen; Enzyme Inhibitors; Gefitinib; Humans; MAP Kinase Kinase Kinases; Melanoma; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Quinazolines; Skin Neoplasms | 2015 |
1 trial(s) available for gefitinib and Melanoma
Article | Year |
---|---|
A phase II study of gefitinib in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Choroid Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Texas; Time Factors; Treatment Outcome; Young Adult | 2011 |
15 other study(ies) available for gefitinib and Melanoma
Article | Year |
---|---|
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Indicators and Reagents; Indoles; Melanoma; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2014 |
Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dinoprostone; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mitochondria; Mutation; Prostaglandin-E Synthases; Proto-Oncogene Proteins B-raf; Pyruvate Carboxylase; Signal Transduction; Skin Neoplasms; Vemurafenib | 2020 |
Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition.
Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HEK293 Cells; Humans; Melanoma; Mice; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Signal Transduction; Up-Regulation; Vemurafenib | 2021 |
uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells.
Topics: Animals; Antigens, CD; Cadherins; Cell Line; Endothelial Cells; ErbB Receptors; Exosomes; Gefitinib; Gene Editing; Humans; Melanoma; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Physiologic; Phosphorylation; Receptors, Urokinase Plasminogen Activator; RNA Interference; RNA, Small Interfering; Signal Transduction | 2021 |
Regulation of miR-21 expression in human melanoma via UV-ray-induced melanin pigmentation.
Topics: alpha-MSH; Animals; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Melanins; Melanoma; Melanoma, Experimental; Mice; MicroRNAs; Phosphorylation; Pigmentation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin Neoplasms; Ultraviolet Rays | 2017 |
Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gefitinib; Humans; Melanoma; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2018 |
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Topics: Antineoplastic Agents; Chloracne; Cytochrome P-450 CYP1A1; Dioxins; Drug Eruptions; Enzyme Activation; Epidermal Cyst; Erlotinib Hydrochloride; Female; Gefitinib; Hep G2 Cells; Humans; Male; Melanoma; Protein Kinase Inhibitors; Skin Neoplasms; Vemurafenib | 2018 |
Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gefitinib; Humans; Melanoma; Quinazolines; Signal Transduction; Transcriptome; Uveal Neoplasms | 2013 |
ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Melanoma; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin Neoplasms; STAT3 Transcription Factor | 2009 |
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Topics: Animals; Antigens; Antineoplastic Agents; Blood Vessels; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; ErbB Receptors; Gefitinib; Humans; Image Processing, Computer-Assisted; Melanoma; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Skin Neoplasms | 2009 |
Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Melanoma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Prediction of synergistic antitumour effect of gefitinib and radiation in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Melanoma; Phosphorylation; Quinazolines; Radiation, Ionizing; Skin Neoplasms | 2011 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2007 |